Cendakimab Antibody is a research-grade biosimilar monoclonal antibody targeting IL13. It is a humanized IgG1-kappa antibody. Reactivity: Human. Supplied as a liquid in 0.01M PBS pH 7.4. Applications: ELISA, flow cytometry, functional assays and in vivo research. Endotoxin: < 10 EU/mg. Purity: >95% as determined by SDS-PAGE. For research use only.
Interleukin-13 (IL13,NC30,Interleukin-13,IL-13) is a ~15 kDa protein. Cytokine that plays important roles in allergic inflammation and immune response to parasite infection. Synergizes with IL2 in regulating interferon-gamma synthesis. Stimulates B-cell proliferation, and activation of eosinophils, basophils, and mast cells. Plays an important role in controlling IL33 activity by modulating the production of transmembrane and soluble forms of interleukin-1 receptor-like 1/IL1RL1. Displays the capacity to antagonize Th1-driven proinflammatory immune response and downregulates synthesis of many proinflammatory cytokines including IL1, IL6, IL10, IL12 and TNF through a mechanism that partially involves suppression of NF-kappa-B.
Product Name:
Cendakimab Antibody
SKU:
GXBS00012
Size:
100 µg, 1 mg
Antibody Type:
Monoclonal Antibody
Target:
IL-13
Isotype:
IgG1-kappa
Host Species:
Human
Reactivity:
Human
Applications:
ELISA, FCM, Functional assay, Research in vivo
Synonyms:
13C5.5, ABT-308, RPC-4046, 2151032-62-9
Purity:
>95% as determined by SDS-PAGE.
Endotoxin Level:
< 10 EU/mg
Formulation:
0.01M PBS pH 7.4.
State of Matter:
Liquid
Regulatory Status:
For research use only. Not suitable for clinical or therapeutic use.
Product Preparation:
Protein A/G purified from cell culture supernatant.
Storage and Handling:
Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
